J
Julia Kerschbaum
Researcher at Innsbruck Medical University
Publications - 50
Citations - 1168
Julia Kerschbaum is an academic researcher from Innsbruck Medical University. The author has contributed to research in topics: Kidney disease & Population. The author has an hindex of 13, co-authored 40 publications receiving 677 citations. Previous affiliations of Julia Kerschbaum include Mayo Clinic.
Papers
More filters
Journal ArticleDOI
Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe.
Kitty J Jager,Anneke Kramer,Nicholas C. Chesnaye,Cécile Couchoud,J. Emilio Sánchez-Álvarez,Liliana Garneata,Frederic Collart,Marc H Hemmelder,Patrice M. Ambühl,Julia Kerschbaum,Camille Legeai,María Dolores del Pino y Pino,Gabriel Mircescu,Lionel Mazzoleni,Tiny Hoekstra,Rebecca Winzeler,Gert Mayer,Vianda S. Stel,Christoph Wanner,Carmine Zoccali,Ziad A. Massy +20 more
TL;DR: The pandemic has had a substantial effect on mortality in patients receiving kidney replacement therapy; a highly vulnerable population due to underlying chronic kidney disease and high prevalence of multimorbidity.
Journal ArticleDOI
Trimethoprim–sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis
Andreas Kronbichler,Julia Kerschbaum,Seerapani Gopaluni,Joanna Tieu,Federico Alberici,Rachel B Jones,Rona M Smith,David Jayne +7 more
TL;DR: Trimethoprim–sulfamethoxazole prophylaxis reduced the risk, while especially bronchiectasis and endobronchial involvement are risk factors for severe respiratory infections, in patients with AAV receiving rituximab.
Journal ArticleDOI
Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic review
Merel E. Hellemons,Julia Kerschbaum,S. J. L. Bakker,Hannes Neuwirt,Bernd Mayer,Gert Mayer,Dick de Zeeuw,H. J. Lambers Heerspink,Michael A. Rudnicki +8 more
TL;DR: In this paper, the authors performed a systematic review to assess the validity of biomarkers predicting the onset or progression of nephropathy in patients with Type 2 diabetes in longitudinal studies.
Journal ArticleDOI
Risk factors associated with peritoneal-dialysis-related peritonitis.
TL;DR: Modifiable and nonmodifiable risk factors analyzed in this paper might serve as a basis to improve patient care in peritoneal dialysis.
Journal ArticleDOI
Rituximab Treatment for Relapsing Minimal Change Disease and Focal Segmental Glomerulosclerosis: A Systematic Review
Andreas Kronbichler,Julia Kerschbaum,Gema Fernandez-Fresnedo,Elion Hoxha,Christine E. Kurschat,Martin Busch,Annette Bruchfeld,Gert Mayer,Michael A. Rudnicki +8 more
TL;DR: Treatment with rituximab (RTX) is effective in reducing the number of relapses and sparing immunosuppression in frequently relapsing and steroid-dependent nephrotic syndrome due to MCD and FSGS.